These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22147731)

  • 1. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
    Myers MV; Manning HC; Coffey RJ; Liebler DC
    Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
    Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
    Feng YH; Tsao CJ; Wu CL; Chang JG; Lu PJ; Yeh KT; Shieh GS; Shiau AL; Lee JC
    Cancer Sci; 2010 Sep; 101(9):2033-8. PubMed ID: 20624167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
    Lu Y; Liang K; Li X; Fan Z
    Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
    Derer S; Berger S; Schlaeth M; Schneider-Merck T; Klausz K; Lohse S; Overdijk MB; Dechant M; Kellner C; Nagelmeier I; Scheel AH; Lammerts van Bueren JJ; van de Winkel JG; Parren PW; Peipp M; Valerius T
    Neoplasia; 2012 Mar; 14(3):190-205. PubMed ID: 22496619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
    Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
    Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
    Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
    Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
    Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
    Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
    Harari PM; Huang SM
    Semin Radiat Oncol; 2001 Oct; 11(4):281-9. PubMed ID: 11677653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cetuximab in the treatment of Menetrier's disease.
    Fiske WH; Tanksley J; Nam KT; Goldenring JR; Slebos RJ; Liebler DC; Abtahi AM; La Fleur B; Ayers GD; Lind CD; Washington MK; Coffey RJ
    Sci Transl Med; 2009 Nov; 1(8):8ra18. PubMed ID: 20368185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.